Amid efforts in Germany to retool the country’s drug spending, the U.S. is launching an investigation into what the Office of the United States Trade Representatives has branded “persistent underpayment” by the European nation for new medications. This inquiry comes as Germany seeks to implement reforms aimed at reducing pharmaceutical costs, which could significantly impact the pricing strategies of drug manufacturers operating within the European market.
The context of this investigation highlights ongoing tensions between the U.S. and European countries regarding drug pricing and reimbursement policies. As Germany moves forward with these reforms, the implications for pharmaceutical companies could be profound, potentially leading to increased scrutiny and adjustments in pricing structures. This situation underscores the delicate balance between cost containment and incentivizing innovation within the global pharmaceutical landscape.
Use the database as your supply chain compass →
